Jonathan Lim, M.D.
Dr. Jonathan Lim is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures dedicated to revitalizing people, planet and perspective. Dr. Lim is a life sciences industry pioneer who has architected transformative advancements in precision oncology and biologics drug delivery. He has served as Chairman and/or CEO and founding investor of six biotechnology companies that have collectively delivered seven approved therapeutic products in oncology, immunology and drug delivery, benefitting thousands of patients globally.
Dr. Lim is a philanthropist and advisor to non-profit organizations through City Hill Foundation and a film producer at City Hill Arts, dedicated to inspiring family entertainment with impact. Earlier in his career, Dr. Lim was a management consultant at McKinsey & Company, an NIH Postdoctoral Fellow at Harvard Medical School and Dana Farber Cancer Institute, and a general surgery resident at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. He holds B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University.
Zachary Hornby
Zachary “Zach” Hornby has served in both operating and director roles for multiple different City Hill portfolio companies. He is currently the Chief Executive Officer, President and a Director at Boundless Bio. He is also a Director at Aardvark Therapeutics. Prior to joining Boundless Bio, Mr. Hornby was Chief Executive Officer, President and a Director at Optera Therapeutics Corp, a company that was developing multiple clinical-stage cellular therapies that had been innovated at MD Anderson Cancer Center. He previously served as Chief Operating Officer at Ignyta, where he oversaw development of the company’s portfolio of four clinical stage therapeutics and was the team leader for the company’s lead program, entrectinib, the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA) and Sakigake (PMDA) designations. Mr. Hornby served in roles of increasing responsibility across business development, marketing, new product planning, finance and regulatory affairs at Fate Therapeutics, Halozyme Therapeutics, Neurocrine Biosciences and TKT (now the Human Genetic Therapies division within Takeda/Shire), and was a life sciences consultant at L.E.K. Consulting. He holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an M.B.A. from Harvard Business School.
Zachary Hornby
Zachary “Zach” Hornby has served in both operating and director roles for multiple different City Hill portfolio companies. He is currently the Chief Executive Officer, President and a Director at Boundless Bio. He is also a Director at Aardvark Therapeutics. Prior to joining Boundless Bio, Mr. Hornby was Chief Executive Officer, President and a Director at Optera Therapeutics Corp, a company that was developing multiple clinical-stage cellular therapies that had been innovated at MD Anderson Cancer Center. He previously served as Chief Operating Officer at Ignyta, where he oversaw development of the company’s portfolio of four clinical stage therapeutics and was the team leader for the company’s lead program, entrectinib, the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA) and Sakigake (PMDA) designations. Mr. Hornby served in roles of increasing responsibility across business development, marketing, new product planning, finance and regulatory affairs at Fate Therapeutics, Halozyme Therapeutics, Neurocrine Biosciences and TKT (now the Human Genetic Therapies division within Takeda/Shire), and was a life sciences consultant at L.E.K. Consulting. He holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an M.B.A. from Harvard Business School.
Conyee Lim, M.D.
Dr. Conyee Lim serves as President of the City Hill Foundation, which she co-founded with Dr. Jonathan Lim in 2011. She served on the Board of Directors of Hope for San Diego , a non-profit organization that engages the San Diego community to care for and invest in its underserved neighbors (2016-2022). Prior to City Hill Foundation, Dr. Lim worked for over 10 years as a hospitalist physician at Kaiser Permanente in Southern California. Her residency training was in internal medicine at New England Medical Center. She holds a B.A. degree in human biology from Stanford University and an M.D. from McGill University.